Inventiva Announces Results of its Mixed General Meeting
The biopharmaceutical company Inventiva has disclosed the voting results of its Mixed General Meeting held on November 27, 2025, according to its press release.
According to Inventiva's press release, all resolutions presented at the Mixed General Meeting were adopted by the shareholders, except for the fifth resolution. This resolution, which had received an unfavorable recommendation from the Board of Directors, proposed to empower the Board to decide on capital increases reserved for members of a savings plan. The quorum for this meeting was 56.432%. Regarding the details of the votes, the first resolution was adopted with 89.783% in favor and 10.217% against, while the fifth resolution was rejected with 41.642% in favor and 58.358% against.
Ordinary and Extraordinary Resolutions
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
According to the results of the ordinary part, resolutions 1, 2, 3, and 6 were adopted. Resolution 6 particularly gathered 99.953% of favorable votes. For the extraordinary resolutions, resolution 4 was also adopted with 89.888% of votes in favor. However, resolution 5 was rejected, highlighting the shareholders' opposition to expanding the Board of Directors' powers concerning capital increases linked to the corporate savings plan.
Company Overview
Inventiva is a company specialized in developing therapies to treat steatohepatitis associated with metabolic dysfunction. The company is listed on Euronext Paris and the Nasdaq Global Market. Currently, its flagship product, Lanifibranor, is undergoing a Phase 3 clinical trial. The results of the Mixed General Meeting reflect a general approval from shareholders for most of the proposed strategies, except for those involving an expansion of the Board's powers regarding savings plans.
Position de trésorerie au 30/09/2025 de 97,6 millions d’euros (plus 24,7 millions d’euros en dépôts à court terme) ; revenus de 4,5 millions d'euros sur les neuf premiers mois de 2025 principalement liés à CTTQ ; flux opérationnels consommés de - 76,3 millions d’euros et flux d'investissement de - 25 millions d’euros ; flux de financement positifs de 103,4 millions d’euros incluant le produit net de la deuxième tranche du financement structuré. Offre publique en novembre 2025 d’ADS apportant un produit net d’environ 139,3 millions d’euros et estimation d’un horizon de trésorerie jusqu’à fin T1 2027 (pouvant aller jusqu’à mi-T3 2027 si exercice intégral de la Tranche 3 pouvant apporter 116,0 millions d'euros).
Risks mentioned
Besoin de capitaux supplémentaires pour financer les opérations
Risque que la Société utilise ses ressources plus rapidement que prévu
Incertitudes et risques liés aux essais cliniques et aux autorisations réglementaires
Dépendance au succès du lanifibranor et des résultats de l'essai NATiV3
Opportunities identified
Produit net de l’offre publique en novembre 2025 d’environ 139,3 millions d’euros renforçant la trésorerie
Exercice potentiel de la Tranche 3 pouvant apporter jusqu’à 116,0 millions d'euros supplémentaires
Paiement d'étape et avoirs liés à l’accord avec CTTQ (10 M$ et 5 M$)
Résultats principaux de l’essai NATiV3 attendus au second semestre 2026
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
